Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice

Gene Therapy

Volumn 14, Issue 2, 2007, Pages 162-172

  Kumar, M ^a,b   Hunag, Y ^a,b   Glinka, Y ^b   Prud'Homme, G J ^b   Wang, Q ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 IMMUNOGLOBULIN G1 HEAVY CHAIN FUSION PROTEIN; GLUCOSE; HYBRID PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; GENE TRANSFER; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RELEASE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLASMID VECTOR; PRIORITY JOURNAL;

ANIMALS; BIOREACTORS; BLOOD GLUCOSE; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; GENE THERAPY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INSULIN; MICE; MICE, OBESE; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

MAMMALIA; MUS;

EID: 33845975658     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302836     Document Type: Article

References (66)

1. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8: 179-188.
2. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
3. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
4. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
5. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999; 140: 1132-1140.
6. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
7. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47: 478-487.
8. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001; 50: 2237-2243.
9. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852-858.
10. Ritzel R, Schulte M, Porksen N, Nauck MS, Holst JJ, Juhl C et al. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 2001; 50: 776-784.
11. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Doseresponse-relationships. Diabetologia 1995; 38: 720-725.
12. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
13. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA et al. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000; 49: 611-617.
14. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825-6830.
15. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-3773.
16. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-14847.
17. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.
18. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
19. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443-1452.
20. Bouckenooghe T, Vandewalle B, Lukowiak B, Kerr-Conte J, Belaich S, Gmyr V et al. Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells. Cell Transplant 2003; 12: 799-807.
21. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
22. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
23. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
24. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999; 140: 1132-1140.
25. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 867-876.
26. Green BD, Gault VA, O'harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 2004; 10: 3651-3662.
27. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52; 2003: 1786-1791.
28. Liu HK, Green BD, Gault VA, McCluskey JT, McClenaghan NH, O'Harte FP et al. N-acetyl-GLP-1: A DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. Cell Biol Int 2004; 28: 69-73.
29. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabet Care 2003; 26: 2370-2377.
30. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-759.
31. Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 2002; 30: 512-516.
32. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999; 21: 75-87.
33. Reimold AM. TNFalpha as therapeutic target: New drugs, more applications. Curr Drug Targets Inflamm Allergy 2002; 1: 377-392.
34. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-820.
35. Dupuis DS, Perez M, Halazy S, Colpaert FC, Pauwels PJ. Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses. Brain Res Mol Brain Res 1999; 67: 107-123.
36. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 20: 1205-1217.
37. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 2000; 106: 207-215.
38. Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Therapy 1999; 6: 771-777.
39. Ozmen L, Gribaudo G, Fountoulakis M, Gentz R, Landolfo S, Garotta G et al. Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol 1993; 150: 2698-2705.
40. Kurschner C, Ozmen L, Garotta G, Dembic Z. IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity. J Immunol 1992; 149: 4096-4100.
41. Kurschner C, Garotta G, Dembic Z. Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules. J Biol Chem 1992; 267: 9354-9360.
42. Jungbauer A, Tauer C, Reiter M, Purtscher M,Wenisch E, Steindl F et al. Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J Chromatogr 1989; 476: 257-268.
43. Baggio L, Kieffer TJ, Drucker DJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 2000; 141: 3703-3709.
44. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159-169.
45. Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P et al. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003; 31: 529-540.
46. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-2539.
47. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
48. Larrick JW, Fry KE. Recombinant antibodies. Hum Antibodies Hybridomas 1991; 2: 172-189.
49. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995; 58: 149-156.
50. Fountoulakis M, Mesa C, Schmid G, Gentz R, Manneberg M, Zulauf M et al. Interferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells. Purification, biochemical characterization, and stoichiometry of binding. J Biol Chem 1995; 270: 3958-3964.
51. Herberg L, Coleman DL. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 1977; 26: 59-99.
52. Chen H, Charlat O, Tartaglia LA,Woolf EA,Weng X, Ellis SJ et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.
53. McIntosh CHS, Pederson RA. Nonisnulin-dependent animal models of diabetes mellitus. In: McNeill JH (ed). Experimental Models of Diabetes. CRC Press: Boca Raton, FL, 1999, pp 337-398.
54. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
55. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48: 2197-2203.
56. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
57. Schick RR, Zimmermann JP, vorm WT, Schusdziarra V. Peptides that regulate food intake: Glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1427-R1435.
58. Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82: 114-117.
59. Ahangari G, Ostadali MR, Rabani A, Rashidian J, Sanati MH, Zarindast MR et al. Growth hormone antibodies formation in patients treated with recombinant human growth hormone. Int J Immunopathol Pharmacol 2004; 17: 33-38.
60. King LB, Monroe JG. Immunobiology of the immature B cell: Plasticity in the B-cell antigen receptor-induced response fine tunes negative selection. Immunol Rev 2000; 176: 86-104.
61. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-290.
62. Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25: 1-18.
63. Prud'homme GJ. Altering immune tolerance therapeutically: The power of negative thinking. J Leukoc Biol 2004; 75: 586-599.
64. Melo MEF, Qian F, El-Amine M, Agarwal RK, Soukhareva N, Kang Y et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002; 168: 4788-4795.
65. Prinz WA, Aslund F, Holmgren A, Beckwith J. The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm. J Biol Chem 1997; 20: 15661-15667.
66. Kurland C, Gallant J. Errors of heterologous protein expression. Curr Opin Biotechnol 1996; 7: 489-493.